BioNTech SE Receives Buy Rating from BMO Capital with $143 Price Target

BioNTech SE received a Buy rating and $143 price target from BMO Capital's Evan Seigerman. The analyst consensus is Moderate Buy with a price target consensus of $140.10, a 25.47% upside from current levels. Corporate insider sentiment is negative with 34 insiders selling their shares over the past quarter.

BioNTech SE (NASDAQ: BNTX), a clinical-stage biotechnology company focused on immunotherapies for cancer and other serious diseases, has received a Buy rating and a $143 price target from BMO Capital's Evan Seigerman. The analyst consensus is a Moderate Buy with a price target consensus of $140.10, representing a 25.47% upside from current levels [3].

The recent strategic transactions have bolstered BioNTech's oncology arm. In June, the company announced a global co-development agreement with Bristol Myers Squibb (BMY) for the investigational bispecific antibody BNT327 for solid tumor types. Under the terms of the agreement, Bristol Myers Squibb will pay BioNTech up to $11.1 billion for the partnership, including $3.5 billion in unconditional payments [2].

Later in the month, BioNTech announced that it would acquire CureVac for approximately $1.25 billion in shares. This acquisition is expected to strengthen BioNTech's research, development, and commercialization of mRNA-based cancer treatments [1].

Despite the positive analyst ratings, corporate insider sentiment is negative with 34 insiders selling their shares over the past quarter [3]. This could be indicative of a potential market correction or a lack of confidence in the company's near-term prospects.

BioNTech's stock has shown resilience, opening at $111.78 on Thursday, with a market cap of $26.87 billion. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18, and a quick ratio of 10.02. The fifty-two week low is $76.53 and the fifty-two week high is $131.49 [3].

Large institutional investors have also shown confidence in BioNTech. Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., and Raymond James Financial Inc. have increased their holdings in the company's stock [3].

References:
[1] https://au.finance.yahoo.com/quote/22UA.HA/chart/
[2] https://finance.yahoo.com/news/recent-agreements-set-bolster-biontech-143045292.html
[3] https://www.marketbeat.com/instant-alerts/biontech-se-sponsored-adr-nasdaqbntx-receives-consensus-recommendation-of-moderate-buy-from-analysts-2025-07-10/